ICD-10-PCS FY2022 code changes
Historical release · ICD-10-PCS FY2022 · Effective October 1, 2021 – March 31, 2022 ICD-10-PCS FY2027 is the release in force (effective October 1, 2026).
Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2022, effective October 1, 2021.
These changes are based on recorded release data. MedCoder does not generate coding changes with AI.
- Release
- ICD-10-PCS FY2022
- Effective
- October 1, 2021
- Code set period
- 2021-10-01 through 2022-03-31
FY2022 at a glance
Compare a code
Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.
Deleted codes — what to report instead
These codes leave the code set on October 1, 2021. Where a successor was determined from the source files it is named below; where none was, that is stated rather than guessed.
No successor was determined for these codes.
| FY2021 (January) code | FY2021 (January) description | FY2022 status | Effective |
|---|---|---|---|
| 30230AZ | Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230G0 | Transfusion of Autologous Bone Marrow into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230G2 | Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230G3 | Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230G4 | Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230H0 | Transfusion of Autologous Whole Blood into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230H1 | Transfusion of Nonautologous Whole Blood into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230J0 | Transfusion of Autologous Serum Albumin into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230J1 | Transfusion of Nonautologous Serum Albumin into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230K0 | Transfusion of Autologous Frozen Plasma into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230K1 | Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230L0 | Transfusion of Autologous Fresh Plasma into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230L1 | Transfusion of Nonautologous Fresh Plasma into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230M0 | Transfusion of Autologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230M1 | Transfusion of Nonautologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230N0 | Transfusion of Autologous Red Blood Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230N1 | Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230P0 | Transfusion of Autologous Frozen Red Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230P1 | Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Q0 | Transfusion of Autologous White Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Q1 | Transfusion of Nonautologous White Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230R0 | Transfusion of Autologous Platelets into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230R1 | Transfusion of Nonautologous Platelets into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230S0 | Transfusion of Autologous Globulin into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230S1 | Transfusion of Nonautologous Globulin into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230T0 | Transfusion of Autologous Fibrinogen into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230T1 | Transfusion of Nonautologous Fibrinogen into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230U2 | Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230U3 | Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230U4 | Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230V0 | Transfusion of Autologous Antihemophilic Factors into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230V1 | Transfusion of Nonautologous Antihemophilic Factors into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230W0 | Transfusion of Autologous Factor IX into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230W1 | Transfusion of Nonautologous Factor IX into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230X0 | Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230X2 | Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230X3 | Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230X4 | Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Y2 | Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Y3 | Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30230Y4 | Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240AZ | Transfusion of Embryonic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240C0 | Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240G0 | Transfusion of Autologous Bone Marrow into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240G2 | Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240G3 | Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240G4 | Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240H0 | Transfusion of Autologous Whole Blood into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240H1 | Transfusion of Nonautologous Whole Blood into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240J0 | Transfusion of Autologous Serum Albumin into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240J1 | Transfusion of Nonautologous Serum Albumin into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240K0 | Transfusion of Autologous Frozen Plasma into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240K1 | Transfusion of Nonautologous Frozen Plasma into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240L0 | Transfusion of Autologous Fresh Plasma into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240L1 | Transfusion of Nonautologous Fresh Plasma into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240M0 | Transfusion of Autologous Plasma Cryoprecipitate into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240M1 | Transfusion of Nonautologous Plasma Cryoprecipitate into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240N0 | Transfusion of Autologous Red Blood Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240N1 | Transfusion of Nonautologous Red Blood Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240P0 | Transfusion of Autologous Frozen Red Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240P1 | Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Q0 | Transfusion of Autologous White Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Q1 | Transfusion of Nonautologous White Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240R0 | Transfusion of Autologous Platelets into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240R1 | Transfusion of Nonautologous Platelets into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240S0 | Transfusion of Autologous Globulin into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240S1 | Transfusion of Nonautologous Globulin into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240T0 | Transfusion of Autologous Fibrinogen into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240T1 | Transfusion of Nonautologous Fibrinogen into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240U2 | Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240U3 | Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240U4 | Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240V0 | Transfusion of Autologous Antihemophilic Factors into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240V1 | Transfusion of Nonautologous Antihemophilic Factors into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240W0 | Transfusion of Autologous Factor IX into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240W1 | Transfusion of Nonautologous Factor IX into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240X0 | Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240X2 | Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240X3 | Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240X4 | Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Y0 | Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Y2 | Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Y3 | Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30240Y4 | Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| 30280B1 | Transfusion of Nonautologous 4-Factor Prothrombin Complex Concentrate into Vein, Open Approach | Deleted — not valid for submission | October 1, 2021 |
| X2C0361 | Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| X2C1361 | Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| X2C2361 | Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| X2C3361 | Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XR2G021 | Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XR2H021 | Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW03321 | Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW03331 | Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW03341 | Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW03351 | Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW033C3 | Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3 | Deleted — not valid for submission | October 1, 2021 |
| XW04321 | Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW04331 | Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW04341 | Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW04351 | Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1 | Deleted — not valid for submission | October 1, 2021 |
| XW043C3 | Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3 | Deleted — not valid for submission | October 1, 2021 |
| XW23346 | Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Deleted — not valid for submission | October 1, 2021 |
| XW23376 | Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Deleted — not valid for submission | October 1, 2021 |
| XW24346 | Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6 | Deleted — not valid for submission | October 1, 2021 |
| XW24376 | Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6 | Deleted — not valid for submission | October 1, 2021 |
Revised descriptions
The code itself is unchanged; its description is not. A reworded title can move which diagnoses belong under it.
Introduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
Introduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
Introduction of Monoclonal Antibody into Peripheral Vein, Open Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
Introduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
Introduction of Monoclonal Antibody into Central Vein, Open Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
Introduction of Monoclonal Antibody into Peripheral Artery, Open Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
Introduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
Introduction of Monoclonal Antibody into Central Artery, Open Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
Introduction of Monoclonal Antibody into Central Artery, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
Introduction of Monoclonal Antibody into Nose, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
Introduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Nose, External Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
Introduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
Introduction of Monoclonal Antibody into Ear, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
Introduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Ear, External Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
Introduction of Monoclonal Antibody into Eye, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
Introduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Eye, External Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
Introduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
Introduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Mouth and Pharynx, External Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
Introduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Upper GI, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Lower GI, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
Introduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
Introduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic
→ Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
Introduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
Introduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
Introduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
Introduction of Monoclonal Antibody into Joints, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
Introduction of Monoclonal Antibody into Bones, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
Introduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
Introduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach
→ Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
Introduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening
→ Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening
The full recorded change list
Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.
Added to the code set (191)
- 00D00ZZ — Extraction of Brain, Open Approach
- 00D03ZZ — Extraction of Brain, Percutaneous Approach
- 00D04ZZ — Extraction of Brain, Percutaneous Endoscopic Approach
- 00D70ZZ — Extraction of Cerebral Hemisphere, Open Approach
- 00D73ZZ — Extraction of Cerebral Hemisphere, Percutaneous Approach
- 00D74ZZ — Extraction of Cerebral Hemisphere, Percutaneous Endoscopic Approach
- 02C03Z7 — Extirpation of Matter from Coronary Artery, One Artery, Orbital Atherectomy Technique, Percutaneous Approach
- 02C13Z7 — Extirpation of Matter from Coronary Artery, Two Arteries, Orbital Atherectomy Technique, Percutaneous Approach
- 02C23Z7 — Extirpation of Matter from Coronary Artery, Three Arteries, Orbital Atherectomy Technique, Percutaneous Approach
- 02C33Z7 — Extirpation of Matter from Coronary Artery, Four or More Arteries, Orbital Atherectomy Technique, Percutaneous Approach
- 02F03ZZ — Fragmentation in Coronary Artery, One Artery, Percutaneous Approach
- 02F13ZZ — Fragmentation in Coronary Artery, Two Arteries, Percutaneous Approach
- 02F23ZZ — Fragmentation in Coronary Artery, Three Arteries, Percutaneous Approach
- 02F33ZZ — Fragmentation in Coronary Artery, Four or More Arteries, Percutaneous Approach
- 02RA0LZ — Replacement of Heart with Biologic and Synthetic Substitute, Autoregulated Electrohydraulic, Open Approach
- 02RA0MZ — Replacement of Heart with Synthetic Substitute, Pneumatic, Open Approach
- 02RH38L — Replacement of Pulmonary Valve with Zooplastic Tissue, In Existing Conduit, Percutaneous Approach
- 02RH38M — Replacement of Pulmonary Valve with Zooplastic Tissue, Native Site, Percutaneous Approach
- 02VL0CZ — Restriction of Left Ventricle with Extraluminal Device, Open Approach
- 02VL0DZ — Restriction of Left Ventricle with Intraluminal Device, Open Approach
- 02VL0ZZ — Restriction of Left Ventricle, Open Approach
- 02VL3CZ — Restriction of Left Ventricle with Extraluminal Device, Percutaneous Approach
- 02VL3DZ — Restriction of Left Ventricle with Intraluminal Device, Percutaneous Approach
- 02VL3ZZ — Restriction of Left Ventricle, Percutaneous Approach
- 02VL4CZ — Restriction of Left Ventricle with Extraluminal Device, Percutaneous Endoscopic Approach
- 02VL4DZ — Restriction of Left Ventricle with Intraluminal Device, Percutaneous Endoscopic Approach
- 02VL4ZZ — Restriction of Left Ventricle, Percutaneous Endoscopic Approach
- 03173ZF — Bypass Right Brachial Artery to Lower Arm Vein, Percutaneous Approach
- 03183ZF — Bypass Left Brachial Artery to Lower Arm Vein, Percutaneous Approach
- 03FG3Z0 — Fragmentation of Intracranial Artery, Percutaneous Approach, Ultrasonic
- 03FG3ZZ — Fragmentation of Intracranial Artery, Percutaneous Approach
- 06LY7CC — Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening
- 06LY7CZ — Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening
- 06LY7DC — Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening
- 06LY7DZ — Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening
- 06LY7ZC — Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening
- 06LY7ZZ — Occlusion of Lower Vein, Via Natural or Artificial Opening
- 06LY8CC — Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
- 06LY8CZ — Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening Endoscopic
- 06LY8DC — Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
- 06LY8DZ — Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
- 06LY8ZC — Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening Endoscopic
- 06LY8ZZ — Occlusion of Lower Vein, Via Natural or Artificial Opening Endoscopic
- 07DT0ZX — Extraction of Bone Marrow, Open Approach, Diagnostic
- 07DT0ZZ — Extraction of Bone Marrow, Open Approach
- 07DT3ZX — Extraction of Bone Marrow, Percutaneous Approach, Diagnostic
- 07DT3ZZ — Extraction of Bone Marrow, Percutaneous Approach
- 0F800ZZ — Division of Liver, Open Approach
- 0F803ZZ — Division of Liver, Percutaneous Approach
- 0F804ZZ — Division of Liver, Percutaneous Endoscopic Approach
- 0F810ZZ — Division of Right Lobe Liver, Open Approach
- 0F813ZZ — Division of Right Lobe Liver, Percutaneous Approach
- 0F814ZZ — Division of Right Lobe Liver, Percutaneous Endoscopic Approach
- 0F820ZZ — Division of Left Lobe Liver, Open Approach
- 0F823ZZ — Division of Left Lobe Liver, Percutaneous Approach
- 0F824ZZ — Division of Left Lobe Liver, Percutaneous Endoscopic Approach
- 0K847ZZ — Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening
- 0K848ZZ — Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening Endoscopic
- 0NH003Z — Insertion of Infusion Device into Skull, Open Approach
- 0NH033Z — Insertion of Infusion Device into Skull, Percutaneous Approach
- 0NH043Z — Insertion of Infusion Device into Skull, Percutaneous Endoscopic Approach
- 0PS403Z — Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
- 0PS443Z — Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
- 0QBN0Z2 — Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
- 0QBN3Z2 — Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
- 0QBN4Z2 — Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
- 0QBP0Z2 — Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach
- 0QBP3Z2 — Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach
- 0QBP4Z2 — Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach
- 0QS003Z — Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach
- 0QS043Z — Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach
- 0RPJ0J6 — Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Open Approach
- 0RPJ0J7 — Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Open Approach
- 0RPJ3J6 — Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Approach
- 0RPJ3J7 — Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
- 0RPJ4J6 — Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
- 0RPJ4J7 — Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
- 0RPK0J6 — Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Open Approach
- 0RPK0J7 — Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Open Approach
- 0RPK3J6 — Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Approach
- 0RPK3J7 — Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
- 0RPK4J6 — Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
- 0RPK4J7 — Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
- 0RWJ0J6 — Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Open Approach
- 0RWJ0J7 — Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Open Approach
- 0RWJ3J6 — Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Approach
- 0RWJ3J7 — Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Approach
- 0RWJ4J6 — Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
- 0RWJ4J7 — Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
- 0RWJXJ6 — Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, External Approach
- 0RWJXJ7 — Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, External Approach
- 0RWK0J6 — Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Open Approach
- 0RWK0J7 — Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Open Approach
- 0RWK3J6 — Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Approach
- 0RWK3J7 — Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Approach
- 0RWK4J6 — Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach
- 0RWK4J7 — Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach
- 0RWKXJ6 — Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, External Approach
- 0RWKXJ7 — Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, External Approach
- 30233D1 — Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Peripheral Vein, Percutaneous Approach
- 30243D1 — Transfusion of Nonautologous Pathogen Reduced Cryoprecipitated Fibrinogen Complex into Central Vein, Percutaneous Approach
- 3E1M48X — Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach, Diagnostic
- 3E1M48Z — Irrigation of Peritoneal Cavity using Irrigating Substance, Percutaneous Endoscopic Approach
- 4B00XW0 — Measurement of Central Nervous Cerebrospinal Fluid Shunt using Wireless Sensor, External Approach
- 5A1221J — Performance of Cardiac Output, Continuous, Automated
- BF150ZZ — Fluoroscopy of Liver using High Osmolar Contrast
- BF151ZZ — Fluoroscopy of Liver using Low Osmolar Contrast
- BF15YZZ — Fluoroscopy of Liver using Other Contrast
- BF15ZZA — Fluoroscopy of Liver, Guidance
- X2CP3T7 — Extirpation of Matter from Abdominal Aorta using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CQ3T7 — Extirpation of Matter from Right Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CR3T7 — Extirpation of Matter from Left Upper Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CS3T7 — Extirpation of Matter from Right Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CT3T7 — Extirpation of Matter from Left Lower Extremity Artery using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CU3T7 — Extirpation of Matter from Right Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CV3T7 — Extirpation of Matter from Left Lower Extremity Vein using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2CY3T7 — Extirpation of Matter from Great Vessel using Computer-aided Mechanical Aspiration, Percutaneous Approach, New Technology Group 7
- X2JAX47 — Inspection of Heart using Transthoracic Echocardiography, Computer-aided Guidance, New Technology Group 7
- X2KB317 — Bypass Right Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
- X2KC317 — Bypass Left Radial Artery using Thermal Resistance Energy, Percutaneous Approach, New Technology Group 7
- X2RX0N7 — Replacement of Thoracic Aorta, Arch using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
- X2V73Q7 — Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7
- X2VW0N7 — Restriction of Thoracic Aorta, Descending using Branched Synthetic Substitute with Intraluminal Device, Open Approach, New Technology Group 7
- XD2G4V7 — Monitoring of Upper GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
- XD2G8V7 — Monitoring of Upper GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
- XD2H4V7 — Monitoring of Lower GI Oxygen Saturation, Percutaneous Endoscopic Approach, New Technology Group 7
- XD2H8V7 — Monitoring of Lower GI Oxygen Saturation, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
- XDPH8K7 — Irrigation of Lower GI using Intraoperative Single-use Oversleeve, Via Natural or Artificial Opening Endoscopic, New Technology Group 7
- XFJB8A7 — Inspection of Hepatobiliary Duct using Single-use Duodenoscope, New Technology Group 7
- XFJD8A7 — Inspection of Pancreatic Duct using Single-use Duodenoscope, New Technology Group 7
- XHRPXF7 — Replacement of Skin with Bioengineered Allogeneic Construct, External Approach, New Technology Group 7
- XNS00C7 — Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
- XNS03C7 — Reposition of Lumbar Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
- XNS40C7 — Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Open Approach, New Technology Group 7
- XNS43C7 — Reposition of Thoracic Vertebra using Posterior (Dynamic) Distraction Device, Percutaneous Approach, New Technology Group 7
- XRGA0R7 — Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
- XRGA3R7 — Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
- XRGA4R7 — Fusion of Thoracolumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
- XRGB0R7 — Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
- XRGB3R7 — Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
- XRGB4R7 — Fusion of Lumbar Vertebral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
- XRGC0R7 — Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
- XRGC3R7 — Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
- XRGC4R7 — Fusion of 2 or more Lumbar Vertebral Joints using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
- XRGD0R7 — Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Open Approach, New Technology Group 7
- XRGD3R7 — Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Approach, New Technology Group 7
- XRGD4R7 — Fusion of Lumbosacral Joint using Customizable Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 7
- XW00X27 — Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7
- XW01397 — Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW01X27 — Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
- XW03357 — Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW03367 — Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW03377 — Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW03387 — Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033A7 — Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033B7 — Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033J7 — Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033K7 — Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033L7 — Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033M7 — Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW033N7 — Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW04357 — Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
- XW04367 — Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
- XW04377 — Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
- XW04387 — Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043A7 — Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043B7 — Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043J7 — Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043K7 — Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043L7 — Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043M7 — Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043N7 — Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW0V0P7 — Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7
- XW133D7 — Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW133E7 — Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
- XW143D7 — Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
- XW143E7 — Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
- XWHD7Q7 — Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7
- XXE0X07 — Measurement of Intracranial Vascular Activity, Computer-aided Assessment, New Technology Group 7
- XXE3X27 — Measurement of Pulmonary Artery Flow, Computer-aided Triage and Notification, New Technology Group 7
- XXE5XR7 — Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
- XXE5XT7 — Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7
- XXE5XV7 — Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7
- XXE97U7 — Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
- XY0YX37 — Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7
Removed from the code set (107)
- 30230AZ — Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach
- 30230C0 — Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Open Approach
- 30230G0 — Transfusion of Autologous Bone Marrow into Peripheral Vein, Open Approach
- 30230G2 — Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach
- 30230G3 — Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach
- 30230G4 — Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach
- 30230H0 — Transfusion of Autologous Whole Blood into Peripheral Vein, Open Approach
- 30230H1 — Transfusion of Nonautologous Whole Blood into Peripheral Vein, Open Approach
- 30230J0 — Transfusion of Autologous Serum Albumin into Peripheral Vein, Open Approach
- 30230J1 — Transfusion of Nonautologous Serum Albumin into Peripheral Vein, Open Approach
- 30230K0 — Transfusion of Autologous Frozen Plasma into Peripheral Vein, Open Approach
- 30230K1 — Transfusion of Nonautologous Frozen Plasma into Peripheral Vein, Open Approach
- 30230L0 — Transfusion of Autologous Fresh Plasma into Peripheral Vein, Open Approach
- 30230L1 — Transfusion of Nonautologous Fresh Plasma into Peripheral Vein, Open Approach
- 30230M0 — Transfusion of Autologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
- 30230M1 — Transfusion of Nonautologous Plasma Cryoprecipitate into Peripheral Vein, Open Approach
- 30230N0 — Transfusion of Autologous Red Blood Cells into Peripheral Vein, Open Approach
- 30230N1 — Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach
- 30230P0 — Transfusion of Autologous Frozen Red Cells into Peripheral Vein, Open Approach
- 30230P1 — Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open Approach
- 30230Q0 — Transfusion of Autologous White Cells into Peripheral Vein, Open Approach
- 30230Q1 — Transfusion of Nonautologous White Cells into Peripheral Vein, Open Approach
- 30230R0 — Transfusion of Autologous Platelets into Peripheral Vein, Open Approach
- 30230R1 — Transfusion of Nonautologous Platelets into Peripheral Vein, Open Approach
- 30230S0 — Transfusion of Autologous Globulin into Peripheral Vein, Open Approach
- 30230S1 — Transfusion of Nonautologous Globulin into Peripheral Vein, Open Approach
- 30230T0 — Transfusion of Autologous Fibrinogen into Peripheral Vein, Open Approach
- 30230T1 — Transfusion of Nonautologous Fibrinogen into Peripheral Vein, Open Approach
- 30230U2 — Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230U3 — Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230U4 — Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230V0 — Transfusion of Autologous Antihemophilic Factors into Peripheral Vein, Open Approach
- 30230V1 — Transfusion of Nonautologous Antihemophilic Factors into Peripheral Vein, Open Approach
- 30230W0 — Transfusion of Autologous Factor IX into Peripheral Vein, Open Approach
- 30230W1 — Transfusion of Nonautologous Factor IX into Peripheral Vein, Open Approach
- 30230X0 — Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Open Approach
- 30230X2 — Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach
- 30230X3 — Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach
- 30230X4 — Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach
- 30230Y0 — Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230Y2 — Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230Y3 — Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30230Y4 — Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach
- 30240AZ — Transfusion of Embryonic Stem Cells into Central Vein, Open Approach
- 30240C0 — Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Open Approach
- 30240G0 — Transfusion of Autologous Bone Marrow into Central Vein, Open Approach
- 30240G2 — Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach
- 30240G3 — Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach
- 30240G4 — Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach
- 30240H0 — Transfusion of Autologous Whole Blood into Central Vein, Open Approach
- 30240H1 — Transfusion of Nonautologous Whole Blood into Central Vein, Open Approach
- 30240J0 — Transfusion of Autologous Serum Albumin into Central Vein, Open Approach
- 30240J1 — Transfusion of Nonautologous Serum Albumin into Central Vein, Open Approach
- 30240K0 — Transfusion of Autologous Frozen Plasma into Central Vein, Open Approach
- 30240K1 — Transfusion of Nonautologous Frozen Plasma into Central Vein, Open Approach
- 30240L0 — Transfusion of Autologous Fresh Plasma into Central Vein, Open Approach
- 30240L1 — Transfusion of Nonautologous Fresh Plasma into Central Vein, Open Approach
- 30240M0 — Transfusion of Autologous Plasma Cryoprecipitate into Central Vein, Open Approach
- 30240M1 — Transfusion of Nonautologous Plasma Cryoprecipitate into Central Vein, Open Approach
- 30240N0 — Transfusion of Autologous Red Blood Cells into Central Vein, Open Approach
- 30240N1 — Transfusion of Nonautologous Red Blood Cells into Central Vein, Open Approach
- 30240P0 — Transfusion of Autologous Frozen Red Cells into Central Vein, Open Approach
- 30240P1 — Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open Approach
- 30240Q0 — Transfusion of Autologous White Cells into Central Vein, Open Approach
- 30240Q1 — Transfusion of Nonautologous White Cells into Central Vein, Open Approach
- 30240R0 — Transfusion of Autologous Platelets into Central Vein, Open Approach
- 30240R1 — Transfusion of Nonautologous Platelets into Central Vein, Open Approach
- 30240S0 — Transfusion of Autologous Globulin into Central Vein, Open Approach
- 30240S1 — Transfusion of Nonautologous Globulin into Central Vein, Open Approach
- 30240T0 — Transfusion of Autologous Fibrinogen into Central Vein, Open Approach
- 30240T1 — Transfusion of Nonautologous Fibrinogen into Central Vein, Open Approach
- 30240U2 — Transfusion of Allogeneic Related T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240U3 — Transfusion of Allogeneic Unrelated T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240U4 — Transfusion of Allogeneic Unspecified T-cell Depleted Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240V0 — Transfusion of Autologous Antihemophilic Factors into Central Vein, Open Approach
- 30240V1 — Transfusion of Nonautologous Antihemophilic Factors into Central Vein, Open Approach
- 30240W0 — Transfusion of Autologous Factor IX into Central Vein, Open Approach
- 30240W1 — Transfusion of Nonautologous Factor IX into Central Vein, Open Approach
- 30240X0 — Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Open Approach
- 30240X2 — Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach
- 30240X3 — Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach
- 30240X4 — Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach
- 30240Y0 — Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240Y2 — Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240Y3 — Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach
- 30240Y4 — Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach
- 30280B1 — Transfusion of Nonautologous 4-Factor Prothrombin Complex Concentrate into Vein, Open Approach
- X2C0361 — Extirpation of Matter from Coronary Artery, One Artery using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
- X2C1361 — Extirpation of Matter from Coronary Artery, Two Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
- X2C2361 — Extirpation of Matter from Coronary Artery, Three Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
- X2C3361 — Extirpation of Matter from Coronary Artery, Four or More Arteries using Orbital Atherectomy Technology, Percutaneous Approach, New Technology Group 1
- XR2G021 — Monitoring of Right Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
- XR2H021 — Monitoring of Left Knee Joint using Intraoperative Knee Replacement Sensor, Open Approach, New Technology Group 1
- XW03321 — Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
- XW03331 — Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1
- XW03341 — Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1
- XW03351 — Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1
- XW033C3 — Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3
- XW04321 — Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
- XW04331 — Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1
- XW04341 — Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
- XW04351 — Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1
- XW043C3 — Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
- XW23346 — Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
- XW23376 — Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
- XW24346 — Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
- XW24376 — Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
Description revised (62)
- 3E00X0M — Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External ApproachIntroduction of Monoclonal Antibody into Skin and Mucous Membranes, External Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
- 3E0130M — Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous ApproachIntroduction of Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
- 3E0230M — Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous ApproachIntroduction of Monoclonal Antibody into Muscle, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
- 3E0300M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open ApproachIntroduction of Monoclonal Antibody into Peripheral Vein, Open Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
- 3E0330M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous ApproachIntroduction of Monoclonal Antibody into Peripheral Vein, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
- 3E0400M — Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open ApproachIntroduction of Monoclonal Antibody into Central Vein, Open Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
- 3E0430M — Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous ApproachIntroduction of Monoclonal Antibody into Central Vein, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
- 3E0500M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open ApproachIntroduction of Monoclonal Antibody into Peripheral Artery, Open Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
- 3E0530M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous ApproachIntroduction of Monoclonal Antibody into Peripheral Artery, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
- 3E0600M — Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open ApproachIntroduction of Monoclonal Antibody into Central Artery, Open Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
- 3E0630M — Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous ApproachIntroduction of Monoclonal Antibody into Central Artery, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
- 3E0930M — Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous ApproachIntroduction of Monoclonal Antibody into Nose, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
- 3E0970M — Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Nose, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
- 3E09X0M — Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External ApproachIntroduction of Monoclonal Antibody into Nose, External Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
- 3E0A30M — Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous ApproachIntroduction of Monoclonal Antibody into Bone Marrow, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
- 3E0B30M — Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous ApproachIntroduction of Monoclonal Antibody into Ear, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
- 3E0B70M — Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Ear, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
- 3E0BX0M — Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External ApproachIntroduction of Monoclonal Antibody into Ear, External Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
- 3E0C30M — Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous ApproachIntroduction of Monoclonal Antibody into Eye, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
- 3E0C70M — Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Eye, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
- 3E0CX0M — Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External ApproachIntroduction of Monoclonal Antibody into Eye, External Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
- 3E0D30M — Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous ApproachIntroduction of Monoclonal Antibody into Mouth and Pharynx, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
- 3E0D70M — Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Mouth and Pharynx, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
- 3E0DX0M — Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External ApproachIntroduction of Monoclonal Antibody into Mouth and Pharynx, External Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
- 3E0E30M — Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous ApproachIntroduction of Monoclonal Antibody into Products of Conception, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
- 3E0E70M — Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
- 3E0E80M — Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Products of Conception, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic
- 3E0F30M — Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous ApproachIntroduction of Monoclonal Antibody into Respiratory Tract, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach
- 3E0F70M — Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening
- 3E0F80M — Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Respiratory Tract, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic
- 3E0G30M — Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous ApproachIntroduction of Monoclonal Antibody into Upper GI, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach
- 3E0G70M — Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening
- 3E0G80M — Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Upper GI, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic
- 3E0H30M — Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous ApproachIntroduction of Monoclonal Antibody into Lower GI, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach
- 3E0H70M — Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening
- 3E0H80M — Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Lower GI, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic
- 3E0J30M — Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous ApproachIntroduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach
- 3E0J70M — Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening
- 3E0J80M — Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic
- 3E0K30M — Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous ApproachIntroduction of Monoclonal Antibody into Genitourinary Tract, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach
- 3E0K70M — Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening
- 3E0K80M — Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic
- 3E0L30M — Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous ApproachIntroduction of Monoclonal Antibody into Pleural Cavity, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach
- 3E0L70M — Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Pleural Cavity, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening
- 3E0M30M — Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous ApproachIntroduction of Monoclonal Antibody into Peritoneal Cavity, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach
- 3E0M70M — Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Peritoneal Cavity, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening
- 3E0N30M — Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous ApproachIntroduction of Monoclonal Antibody into Male Reproductive, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach
- 3E0N70M — Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening
- 3E0N80M — Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Male Reproductive, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0P30M — Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous ApproachIntroduction of Monoclonal Antibody into Female Reproductive, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach
- 3E0P70M — Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening
- 3E0P80M — Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening EndoscopicIntroduction of Monoclonal Antibody into Female Reproductive, Via Natural or Artificial Opening Endoscopic → Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic
- 3E0Q00M — Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open ApproachIntroduction of Monoclonal Antibody into Cranial Cavity and Brain, Open Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach
- 3E0Q30M — Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous ApproachIntroduction of Monoclonal Antibody into Cranial Cavity and Brain, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach
- 3E0Q70M — Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Cranial Cavity and Brain, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening
- 3E0R30M — Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous ApproachIntroduction of Monoclonal Antibody into Spinal Canal, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach
- 3E0S30M — Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous ApproachIntroduction of Monoclonal Antibody into Epidural Space, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach
- 3E0U30M — Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous ApproachIntroduction of Monoclonal Antibody into Joints, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach
- 3E0V30M — Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous ApproachIntroduction of Monoclonal Antibody into Bones, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach
- 3E0W30M — Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous ApproachIntroduction of Monoclonal Antibody into Lymphatics, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach
- 3E0Y30M — Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous ApproachIntroduction of Monoclonal Antibody into Pericardial Cavity, Percutaneous Approach → Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach
- 3E0Y70M — Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial OpeningIntroduction of Monoclonal Antibody into Pericardial Cavity, Via Natural or Artificial Opening → Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening
Sources
Official source data
- Publisher
- Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
- Release
- ICD-10-PCS FY2022
- File checksum (SHA-256)
- eab96ad197cd22e10ac6a610fe5ce6b5b2a55286466904e8e9c711f223dc9a70
- Rebuilt snapshot
- CMS replaced the original October 2021 code file with its December 2021 update. The snapshot compared here is that file without the 7 codes its addenda add effective April 1, 2022.
- Data type
- Public domain code descriptions and tabular instructions. No licensed content.
MedCoder-derived analysis
- Change detection
- Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
- Editorial analysis
- The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
- Independence
- MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.
Continue
Cite this page
Reference this page in a research guide, syllabus or article. The release is included because code content changes each year.
MedCoder.ai. "ICD-10-PCS FY2022 code changes." ICD-10-PCS FY2022. https://medcoder.ai/updates/icd10pcs/icd10pcs-fy2022